Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.73 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.73 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.73 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | AR | P10275 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone SCHEMBL14577661 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL19510084 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL5021649 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL14074493 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL7768886 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL24476231 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL6834811 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11781372 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL9161897 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNACYP2C19ABCB11PGR | |
| Norethindrone SCHEMBL11291575 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNACYP2C19ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 98574 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099483-A1 | A READY-TO-USE DRUG DELIVERY SYSTEM | SEVER PHARMA SOLUTIONS (SE) | 2026-05-15 | — | — | WO | claimed |
| EP-4739292-A1 | A THREE-LAYERED INTRAVAGINAL RING | Sever Pharma Solutions (SE) | 2026-05-13 | — | — | EP | claimed |
| CN-122009499-A | Light mixed working medium for liquid metal strong precooling system and preparation method thereof | 中国航空发动机研究院 | 2026-05-12 | — | — | CN | claimed |
| US-12616703-B2 | Methods of contraception using nomegestrol acetate and estradiol | Theramex HQ UK Limited (GB) | 2026-05-05 | — | — | US | claimed |
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260090995-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | ESTETRA SRL (BE) | 2026-04-02 | — | — | US | claimed |
| US-20260091041-A1 | Methods of Treating Heavy Menstrual Bleeding | ABBVIE INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091036-A1 | Dosing Regimens for Elagolix | ABBVIE INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076896-A1 | CONTINUOUS OR PERIODICAL TRANSDERMAL DELIVERY OF EXOGENOUS MOLECULE | KIFFIK BIOMEDICAL INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3782394-B1 | UE CONTROLLED HANDLING OF THE SECURITY POLICY FOR USER PLANE PROTECTION IN 5G SYSTEMS | ERICSSON TELEFON AB L M (SE) | 2026-03-04 | — | — | EP | claimed |
| US-4054651-A | Method of contraception | RICHARDSON-MERRELL INC. (US) | 1977-10-18 | — | — | US | claimed |
| US-4036228-A | Osmotic dispenser with gas generating means | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-4018919-A | IN MAMMALS | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | claimed |
| US-4016270-A | Method for treating dysmenorrhea with a uterine therapeutic system | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | claimed |
| US-4016057-A | ELECTROLYZING | FUJI PHOTO FILM CO., LTD. (JA) | 1977-04-05 | — | — | US | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3942641-A | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-03-09 | — | — | US | claimed |
| US-3939258-A | Process for the manufacture of human transferrin labelled with indium 113m | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | claimed |
| US-3933678-A | Optically clear organosilicon compounds | DOW CORNING CORPORATION (US) | 1976-01-20 | — | — | US | claimed |
| US-3932635-A | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-01-13 | — | — | US | claimed |